Lupin Pharma to launch Fyavolv TM Tablets

Aadhira Anandh | The Dollar Business

Lupin Pharma, the fastest growing generic drug maker has announced the launch of Fyavolv TM Tablets. The tablet is used in the treatment of vasomotor symptoms due to menopause and also for the prevention of postmenopausal osteoporosis.

“The drug is an oral contraceptive indicated for the treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis. The launch of our new drug increases accessibility to the product and provides patient with a quality option.” said, Shamsher Gorawara, spokesperson of Lupin Pharmaceuticals.

Lupin on Monday announced that, its US subsidiary, Lupin Pharmaceuticals Inc. will launch the tablet in US. The generic drug maker had earlier received the approval from United States Food and Drug administration (FDA) to promote the generic version of Warner Chilcott's Femhrt® Tablets.

Shamsher Gorawara, added, “Lupin has always been committed to the Women’s health in the United States of America. We have made over 35 filings for Oral Contraceptives with the US FDA, with 15 filings pending approval. We have the largest product portfolio for oral contraceptives and have established strong brand equity by delivering good quality products for the segment.”

Fyavolv Tablet of Lupin is the generic alternative for the Warner’ s Femhrt® Tablets. Femhrt, Warners’s tablet has a sale of $39 million in US. 

Lupin is one of the largest generic drug maker in the market and is headquartered in Mumbai. Lupin’s turnover for the previous fiscal March 2015, was USD 2.06 billion.

Lupin is the sixth largest generic drug maker and also falls among the fastest growing top 10 generic drug makers in US. Also Lupin is the third largest pharmaceutical company in India for its sales.

Lupin is a significant player in diabetology, cardiovascular, asthma, CNS, paediatric, anti-infective and in the NSAID space. The company also holds a global leadership position in the Cephalosporin segment and in the Anti-TB segment.